Chiesi Farmaceutici

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase III Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated released favorable top-line findings from the SEQUOIA-HCM trial (Safety, Efficacy, and Quantitative Understanding of Obst...

Ipsen to Acquire Albireo for USD 952 Million Ipsen, a French pharmaceutical company, has offered USD 42 per share for the US biotech Albireo and its rare disease treatment Bylvay, continuing a recent spree of merger and acquisition activity. Albireo, a Boston-based business, is valued at USD 952 million under th...

Every time an opioid therapy is in the option for any patient to overcome the pain due to some chronic ailment, the risk of opioid abuse, misuse, or dependence always lingers at the back of mind. After termination of the opioids, the patient finds it difficult to stop the use of drugs and begins to crave for it. Th...

The year 2016, around 48.5 million Americans older than 12 years, reported to be actively abusing prescription opioids or involved in illicit drug use, says CDC drug surveillance report. The toll has been increasing and is almost impossible to ignore. It is disheartening to note that between the period between 1999...